Literature DB >> 30265285

TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.

D B Costa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30265285      PMCID： PMC6225888          DOI： 10.1093/annonc/mdy339

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  31 in total

Review 1.  How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.

Authors:  Thorsten Stiewe; Tali E Haran
Journal:  Drug Resist Updat       Date:  2018-05-09       Impact factor: 18.500

2.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Authors:  Zhao Chen; Katherine Cheng; Zandra Walton; Yuchuan Wang; Hiromichi Ebi; Takeshi Shimamura; Yan Liu; Tanya Tupper; Jing Ouyang; Jie Li; Peng Gao; Michele S Woo; Chunxiao Xu; Masahiko Yanagita; Abigail Altabef; Shumei Wang; Charles Lee; Yuji Nakada; Christopher G Peña; Yanping Sun; Yoko Franchetti; Catherine Yao; Amy Saur; Michael D Cameron; Mizuki Nishino; D Neil Hayes; Matthew D Wilkerson; Patrick J Roberts; Carrie B Lee; Nabeel Bardeesy; Mohit Butaney; Lucian R Chirieac; Daniel B Costa; David Jackman; Norman E Sharpless; Diego H Castrillon; George D Demetri; Pasi A Jänne; Pier Paolo Pandolfi; Lewis C Cantley; Andrew L Kung; Jeffrey A Engelman; Kwok-Kin Wong
Journal:  Nature       Date:  2012-03-18       Impact factor: 49.962

3.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Authors:  Deepa Rangachari; Norihiro Yamaguchi; Paul A VanderLaan; Erik Folch; Anand Mahadevan; Scott R Floyd; Erik J Uhlmann; Eric T Wong; Suzanne E Dahlberg; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2015-02-04       Impact factor: 5.705

4.  De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

Authors:  Brian J Carney; Deepa Rangachari; Paul A VanderLaan; Kyle Gowen; Alexa B Schrock; Siraj M Ali; Daniel B Costa
Journal:  Lung Cancer       Date:  2017-08-24       Impact factor: 5.705

5.  Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.

Authors:  Helena A Yu; Ken Suzawa; Emmet Jordan; Ahmet Zehir; Ai Ni; Ryan Kim; Mark G Kris; Matthew D Hellmann; Bob T Li; Romel Somwar; David B Solit; Michael F Berger; Maria Arcila; Gregory J Riely; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2018-03-12       Impact factor: 12.531

6.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

7.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

8.  Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Authors:  Jessica J Lin; Viola W Zhu; Satoshi Yoda; Beow Y Yeap; Alexa B Schrock; Ibiayi Dagogo-Jack; Nicholas A Jessop; Ginger Y Jiang; Long P Le; Kyle Gowen; Philip J Stephens; Jeffrey S Ross; Siraj M Ali; Vincent A Miller; Melissa L Johnson; Christine M Lovly; Aaron N Hata; Justin F Gainor; Anthony J Iafrate; Alice T Shaw; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2018-01-26       Impact factor: 44.544

9.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

10.  Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Authors:  Alice T Shaw; Enriqueta Felip; Todd M Bauer; Benjamin Besse; Alejandro Navarro; Sophie Postel-Vinay; Justin F Gainor; Melissa Johnson; Jorg Dietrich; Leonard P James; Jill S Clancy; Joseph Chen; Jean-François Martini; Antonello Abbattista; Benjamin J Solomon
Journal:  Lancet Oncol       Date:  2017-10-23       Impact factor: 41.316
View more
  3 in total

1.  Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients.

Authors:  Junnan Feng; Yan Li; Bing Wei; Lei Guo; Weihua Li; Qingxin Xia; Chengzhi Zhao; Jiawen Zheng; Jiuzhou Zhao; Rui Sun; Yongjun Guo; Luka Brcic; Taiki Hakozaki; Jianming Ying; Jie Ma
Journal:  Transl Lung Cancer Res       Date:  2022-04

2.  Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature.

Authors:  Xi Lei; Shuai Zhu; Dian Ren; Fan Ren; Tong Li; Ning Zhou; Shuo Li; Tao Shi; Lingling Zu; Zuoqing Song; Justyna Chalubinska-Fendler; Marc G Denis; Eric H Bernicker; Vincent Thomas de Montpréville; Richeng Jiang; Song Xu
Journal:  Transl Lung Cancer Res       Date:  2022-06

3.  Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.

Authors:  Balázs Jóri; Markus Falk; Iris Hövel; Peggy Weist; Markus Tiemann; Lukas C Heukamp; Frank Griesinger
Journal:  Curr Oncol       Date:  2022-09-16       Impact factor: 3.109
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.